Novel investigational therapies for atopic dermatitis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2015-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2015.957756PMID 25201033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vitamin D deficiency is associated with diagnosis and severity of childhood atopic dermatitis

  2014cited by this paper
• Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients.

  2014cited by this paper
• Is adult atopic eczema more common than we think? - A population-based study in Danish adults.

  2014cited by this paper
• Role of prostaglandin D2 and CRTH2 blockade in early‐ and late‐phase nasal responses

  2014cited by this paper
• Th17 cells and tissue remodeling in atopic and contact dermatitis

  2014cited by this paper
• Systemic therapy for atopic dermatitis

  2014cited by this paper
• Lipid abnormalities and lipid-based repair strategies in atopic dermatitis.

  2014cited by this paper
• Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

  2014cited by this paper
• Ustekinumab in the Treatment of Severe Atopic Dermatitis: A Preliminary Report of Our Experience With 4 Patients

  2014cited by this paper
• Increased efficacy of omalizumab in atopic dermatitis patients with wild‐type filaggrin status and higher serum levels of phosphatidylcholines

  2014influential reference
• Immunologic Effects of Omalizumab in Children With Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial

  2014cited by this paper
• Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.

  2014cited by this paper
• Ustekinumab en el tratamiento de la dermatitis atópica severa. Nuestra experiencia en 4 pacientes. Informe preliminar

  2014cited by this paper
• Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial

  2013cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels.

  2013cited by this paper
• Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.

  2013cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels

  2013cited by this paper
• Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis

  2013cited by this paper
• Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab

  2013cited by this paper
• Management of difficult-to-treat atopic dermatitis.

  2013cited by this paper
• Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

  2013cited by this paper
• Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis

  2013cited by this paper
• Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor

  2013cited by this paper
• Anti‐immunoglobulin E in the treatment of refractory atopic dermatitis

  2013influential reference
• The European treatment of severe atopic eczema in children taskforce (TREAT) survey

  2013cited by this paper
• CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils.

  2012cited by this paper
• A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

  2012cited by this paper
• Filaggrin mutations and atopy: consequences for future therapeutics

  2012cited by this paper
• A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.

  2012cited by this paper
• Efficacy and safety of topical WBI‐1001 in patients with mild to severe atopic dermatitis: results from a 12‐week, multicentre, randomized, placebo‐controlled double‐blind trial

  2012cited by this paper
• Treatment of severe refractory adult atopic dermatitis with ustekinumab

  2012cited by this paper
• An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial

  2012cited by this paper
• Omalizumab for the treatment of atopic dermatitis.

  2012cited by this paper
• Exacerbation of atopic dermatitis in a patient treated with infliximab.

  2012cited by this paper
• An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial.

  2011cited by this paper
• Pathophysiology of itch and new treatments

  2011cited by this paper
• Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema

  2010cited by this paper
• Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy

  2010cited by this paper
• Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

  2010cited by this paper
• A new moisturizer containing physiologic lipid granules alleviates atopic dermatitis

  2010cited by this paper
• Rituximab: mechanism of action.

  2010cited by this paper
• Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

  2010influential reference
• New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression

  2010cited by this paper
• Expression of neuropeptides and their degrading enzymes in ACD

  2010cited by this paper
• Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study

  2010cited by this paper
• ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis

  2010cited by this paper
• Increased expression of CRTH2 on eosinophils in allergic skin diseases

  2010cited by this paper
• Anti‐interleukin‐31‐antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis

  2009cited by this paper
• Treatment with a barrier‐strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial

  2009cited by this paper
• Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy.

  2009cited by this paper
• Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

  2009cited by this paper
• Anti-CD20 (rituximab) treatment improves atopic eczema.

  2008cited by this paper
• Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.

  2008cited by this paper
• Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

  2008cited by this paper
• The role of selected neuropeptides in pathogenesis of atopic dermatitis

  2007cited by this paper
• Two cases of atopic dermatitis‐like conditions induced in psoriasis patients treated with infliximab

  2007cited by this paper
• The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation.

  2006cited by this paper
• Life quality assessment among patients with atopic eczema

  2006cited by this paper
• Infliximab in the treatment of moderate to severe atopic dermatitis.

  2005cited by this paper
• Association study of mast cell chymase polymorphisms with atopy

  2005cited by this paper
• Involvement of substance P in scratching behaviour in an atopic dermatitis model.

  2004cited by this paper
• Systemic therapy of atopic dermatitis

  2000cited by this paper
• Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease

  1999cited by this paper
• Molecular regulation of human IgE synthesis

  1999cited by this paper
• Molecular regulation of human IgE synthesis

  1997cited by this paper
• Association between genetic variants of mast-cell chymase and eczema.

  1996cited by this paper
• Interleukin-1 receptor antagonist.

  1993cited by this paper
• Relationship between increased cyclic AMP-phosphodiesterase activity and abnormal adenylyl cyclase regulation in leukocytes from patients with atopic dermatitis.

  1992cited by this paper
• Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.

  1991cited by this paper
• Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.

  1982cited by this paper

• Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy.

  2024cites this paper
• Adipokine-Enriched Adipose Extract Restores Skin Barrier and Ameliorates Inflammatory Dysregulation in Atopic Dermatitis Mice

  2023cites this paper
• Biologics in Dermatology: Off-Label Indications

  2020cites this paper
• A Phytocomplex Consisting of Tropaeolum majus L. and Salvia officinalis L. Extracts Alleviates the Inflammatory Response of Dermal Fibroblasts to Bacterial Lipopolysaccharides

  2020cites this paper
• Atopic dermatitis: a review of evolving targeted therapies

  2019cites this paper
• Insights into future therapeutics for atopic dermatitis

  2018cites this paper
• Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential

  2017cites this paper
• Expression of TNFα Receptors on Immunocompetent Cells Is Increased in Atopic Dermatitis

  2017cites this paper
• Novel Therapeutic Approaches to Atopic Dermatitis

  2017cites this paper
• Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects

  2017cites this paper
• Biological Therapeutic Treatment of Atopic Dermatitis

  2017cites this paper
• Emerging small-molecule compounds for treatment of atopic dermatitis: a review

  2016cites this paper
• Chitosan/poly(vinyl alcohol)/bovine bone powder biocomposites: A potential biomaterial for the treatment of atopic dermatitis-like skin lesions.

  2016cites this paper
• Fluoxetine Ameliorates Atopic Dermatitis-Like Skin Lesions in BALB/c Mice through Reducing Psychological Stress and Inflammatory Response

  2016cites this paper
• Topical Application of Angelica sinensis Improves Pruritus and Skin Inflammation in Mice with Atopic Dermatitis-Like Symptoms

  2016cites this paper
• From the morphological to the transcriptomic characterization of a compromised three‐dimensional in vitro model mimicking atopic dermatitis

  2015cites this paper
• Biological Treatments in Atopic Dermatitis

  2015influential citation
• Pathogeneseorientierte moderne Therapie der atopischen Dermatitis

  2015cites this paper
• Status quo und Perspektiven der systemischen Therapie der atopischen Dermatitis

  2015cites this paper
• Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch

  2015cites this paper